Last Updated: June 22, 2026

DYANAVEL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Dyanavel, and what generic alternatives are available?

Dyanavel is a drug marketed by Tris Pharma Inc and is included in two NDAs. There are eleven patents protecting this drug.

The generic ingredient in DYANAVEL is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Dyanavel

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for DYANAVEL?
  • What are the global sales for DYANAVEL?
  • What is Average Wholesale Price for DYANAVEL?
Summary for DYANAVEL
US Patents:0
Applicants:1
NDAs:2
Drug Prices: Drug price information for DYANAVEL
DailyMed Link:DYANAVEL at DailyMed

US Patents and Regulatory Information for DYANAVEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc DYANAVEL XR amphetamine; amphetamine aspartate/dextroamphetamine sulfate SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Tris Pharma Inc DYANAVEL XR 20 amphetamine; amphetamine aspartate/dextroamphetamine sulfate TABLET, EXTENDED RELEASE;ORAL 210526-004 Nov 4, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Tris Pharma Inc DYANAVEL XR 5 amphetamine; amphetamine aspartate/dextroamphetamine sulfate TABLET, EXTENDED RELEASE;ORAL 210526-001 Nov 4, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Tris Pharma Inc DYANAVEL XR amphetamine; amphetamine aspartate/dextroamphetamine sulfate SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.